Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Who We Are
    • IP Portfolio
    • Management Team
    • Board of Directors
    • Careers
  • Technology
  • Pipeline
    • Kappa Opioid Receptor Agonist
    • Nalmefene Implant
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Publications
    • Posters
    • Media Resources
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Search
  • Twitter

Press Releases

  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Navigate Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Titan Pharmaceuticals to Receive $3 Million Loan

December 21, 2009

Titan Receives Notice of Allowance for Probuphine(R) Patent Application in the Treatment of Opiate Addiction

November 30, 2009

Novartis Pharma Acquires Exclusive Rights From Vanda Pharmaceuticals for Commercialization of Fanapt(TM) in the United States and Canada

October 13, 2009

Titan Announces Award of NIH Grant for Probuphine(R) Clinical Development

October 1, 2009

Titan Re-Engages Key Executives

May 20, 2009

Titan Announces FDA Approval of Fanapt(TM) (Iloperidone) For the Treatment of Schizophrenia

May 7, 2009

RSS
  • « Previous
  • 1...
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
© 2023 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap Twitter